Insider Trading April 8, 2026 12:52 PM

Ceribell CEO Disposes $717,600 in Stock; Exercises Options for 25,000 Shares

Chao Xingjuan completed a Rule 10b5-1 sale of 39,000 shares and exercised options amid a recent share-price rally

By Ajmal Hussain CBLL
Ceribell CEO Disposes $717,600 in Stock; Exercises Options for 25,000 Shares
CBLL

Ceribell President and CEO Chao Xingjuan sold 39,000 shares of common stock on April 6, 2026, under a pre-arranged Rule 10b5-1 plan for a weighted average price of $18.40, totaling $717,600. On the same day she exercised options to purchase 25,000 shares at $4.70 per share for $117,500. After the transactions, Chao directly holds 850,347 shares and indirectly owns 369,088 shares through the ACP 2021 Trust. The company's stock has risen 46% over the past six months, while InvestingPro deems the shares overvalued relative to their Fair Value.

Key Points

  • Ceribell CEO Chao Xingjuan sold 39,000 shares on April 6, 2026, under a pre-arranged Rule 10b5-1 plan for total proceeds of $717,600 at a weighted average price of $18.40 per share.
  • On the same day, she exercised options to purchase 25,000 shares at $4.70 per share for $117,500; after these actions she directly owns 850,347 shares and indirectly holds 369,088 shares via the ACP 2021 Trust.
  • The company's stock has risen 46% over the past six months, and InvestingPro analysis indicates the shares are currently trading above their Fair Value estimate - relevant to the medical device and healthcare equipment sectors as well as equity market observers.

Transaction details

Ceribell, Inc. (NASDAQ: CBLL) disclosed that President and Chief Executive Officer Chao Xingjuan sold a total of 39,000 shares of the company’s common stock on April 6, 2026. The aggregate proceeds reported for the sale were $717,600, based on a weighted average sale price of $18.40 per share. According to the Form 4 filed with the Securities and Exchange Commission, the sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan.

The filing lists the individual sale prices as ranging from $18.03 to $18.77. The Form 4 clarifies that the $18.40 figure represents a weighted average price across multiple transactions executed that day.

Option exercise

Also on April 6, Chao exercised options to acquire 25,000 shares of Ceribell common stock at an exercise price of $4.70 per share, for an aggregate exercise cost of $117,500. The co-occurrence of a stock sale and option exercise on the same date is recorded in the SEC filing.

Post-transaction holdings

Following the sales and exercise, Chao is reported to directly own 850,347 shares of Ceribell common stock. In addition, she is shown as indirectly holding 369,088 shares through the ACP 2021 Trust, as stated in the disclosure.

Context from market data and research

The company’s share price has advanced 46% over the last six months, a rise noted alongside the insider transactions. InvestingPro analysis cited in the disclosure indicates that Ceribell’s stock is currently valued above its Fair Value estimate, according to that service.

Research availability

Investors seeking additional valuation and performance detail are pointed to a comprehensive Pro Research Report that is available for Ceribell and more than 1,400 other U.S. equities, as noted in the original disclosure.


Note: The prices, share counts and ownership figures above are taken from the company’s SEC Form 4 filing and related disclosures filed for the transactions dated April 6, 2026.

Risks

  • Insider selling may be interpreted by market participants as a change in insider liquidity - this directly impacts investor perception within the healthcare and small-cap equity market segments.
  • InvestingPro's assessment that the stock is overvalued relative to its Fair Value highlights valuation risk for prospective buyers in the medical device sector; valuation dynamics could influence trading behavior and capital allocation decisions.
  • The disclosures do not state the CEO's motives for the sale or the exercise beyond the mechanics recorded in the Form 4; the lack of stated intent introduces uncertainty for shareholders and analysts attempting to infer strategic rationale.

More from Insider Trading

Monolithic Power Systems Executive Disposes $8.9M in Stock as Analysts Raise Targets After Strong Quarter Apr 8, 2026 Insider Jorey Chernett Buys $175,800 of Airsculpt Technologies Stock Apr 8, 2026 Lightwave Logic Director Sells 11,000 Shares to Cover RSU Taxes Amid Rapid Stock Run-Up Apr 8, 2026 Japan Post Holdings Disposes of 21,500 Aflac Shares for $2.37 Million Apr 8, 2026 MeiraGTx Development Chief Disposes $258,906 in Shares as Stock Nears Yearly High Apr 7, 2026